ASCO 2014: Dr. Kipps Discusses ROR1 and Inform... - CLL Support

CLL Support

23,340 members40,049 posts

ASCO 2014: Dr. Kipps Discusses ROR1 and Information about a New ROR1 Monoclonal Antibody (cirmtuzumab) Trial in Relapsed and Refractory CLL

bkoffman profile image
bkoffmanCLL CURE Hero
3 Replies

Friends,

Cirmtuzumab, a ROR1 monoclonal antibody is finally here in a Phase 1 clinical trial at UCSD after years of promise. The hope is that it will be as effective and targeted in real patients as it has been in the lab. Its promise is that it will just massively kill the CLL clone and spare the normal B cells unlike the CD20 mAb, whatever generation. That would be a real bonus, but it is a Phase 1 trial.

On my blog (bkoffman.blogspot.com ), I review the back story of ROR1with a video interview with Dr. Kipps and discuss more about the ethical design of Phase 1 trials.

Stay strong

Brian

bkoffman.blogspot.com

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
3 Replies
AussieNeil profile image
AussieNeilPartnerAdministrator

Here's the news release from the University of California, San Diego (UCSD) on ROR1:

health.ucsd.edu/news/releas...

Neil

PS Brian, I've edited your above post to include spaces between the brackets and the link to your blog so the link works.

bkoffman profile image
bkoffmanCLL CURE Hero in reply toAussieNeil

Thanks.

jangreen profile image
jangreen

Hi I have heard of this protein before and if successful this, as I understand it, would make our own immune system kill off the Cll cells without damage to other cells. In other words our own immune system would act "normal". Thank for the video.

Not what you're looking for?

You may also like...

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
AussieNeil profile image
Partner

ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL

Friends, I am stuck at the airport on my way to OSU waiting for my delayed flight, so I thought I...
bkoffman profile image
CLL CURE Hero

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

Oncology live May 06, 2020 The time-limited triplet of umbralisib, ublituximab, and venetoclax...
Jm954 profile image
Administrator

Three Year Anniversary on Ibrutinib for my CLL

Friends, Three years ago today I started on ibrutinib as part of a trial out of OSU, and life just...
bkoffman profile image
CLL CURE Hero

Starting CAR-T therapy for my relapsing CLL

Friends and CLL Society supporters: This isn't easy. After consulting with my wife, my family, my...
bkoffman profile image
CLL CURE Hero